Affinity Investment Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-21,923
Closed -$337K – 157
2025
Q1
$337K Buy
21,923
+3,356
+18% +$59.9K 0.27% 102
2024
Q4
$409K Buy
18,567
+2,376
+15% +$43.2K 0.34% 92
2024
Q3
$292K Hold
16,191
– – 0.2% 114
2024
Q2
$263K Sell
16,191
-8,626
-35% -$133K 0.2% 112
2024
Q1
$350K Hold
24,817
– – 0.26% 101
2023
Q4
$259K Buy
24,817
+636
+3% +$5.94K 0.18% 158
2023
Q3
$247K Sell
24,181
-7,336
-23% -$68.3K 0.16% 169
2023
Q2
$237K Buy
+31,517
New +$256K 0.14% 179

Other funds holding TEVA

Affinity Investment Advisors's TEVA Position: Q2 2025 in Review

Affinity Investment Advisors sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2025, closing a stake of 21,923 shares — an estimated $337K sold.

Affinity Investment Advisors first reported a position in TEVA in Q2 2023 and held it in 8 quarters. The position peaked at $409K in Q4 2024. 541 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Affinity Investment Advisors reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2025 after selling out during the quarter.
  • Affinity Investment Advisors sold 21,923 Teva Pharmaceutical Industries Limited shares in Q2 2025, an estimated $337K.
  • Affinity Investment Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q2 2023 and held it in 8 quarters.
  • Affinity Investment Advisors's Teva Pharmaceutical Industries Limited position peaked at $409K in Q4 2024.
  • 541 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2025.

Based on Affinity Investment Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.